Literature DB >> 31622621

Therapeutic Targeting of the Colorectal Tumor Stroma.

Wolf H Fridman1, Ian Miller2, Catherine Sautès-Fridman3, Annette T Byrne2.   

Abstract

Colorectal tumors have been classified based on histologic factors, genetic factors, and consensus molecular subtypes, all of which affect the tumor microenvironment. Elements of the tumor microenvironment serve as therapeutic targets and might be used as prognostic factors. For example, immune checkpoint inhibitors are used to treat tumors with microsatellite instability, and anti-angiogenic agents may be used in combination with other drugs to slow or inhibit tumor growth. We review the features of the colorectal tumor stroma that are associated with patient outcomes and discuss potential therapeutic agents that target these features.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRC; MSI; Matrix; Microenvironment

Mesh:

Substances:

Year:  2019        PMID: 31622621     DOI: 10.1053/j.gastro.2019.09.045

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

1.  SP1-mediated up-regulation of lncRNA TUG1 underlines an oncogenic property in colorectal cancer.

Authors:  Wei Liu; Jin Meng; Rongjun Su; Changjun Shen; Shuai Zhang; Yantao Zhao; Wenqi Liu; Jiang Du; Shuai Zhu; Pan Li; Zhigang Wang; Xiaoxia Li
Journal:  Cell Death Dis       Date:  2022-05-04       Impact factor: 9.685

Review 2.  The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.

Authors:  Florent Petitprez; Maxime Meylan; Aurélien de Reyniès; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

3.  microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis.

Authors:  Caifeng Yue; Jierong Chen; Ziyue Li; Laisheng Li; Jugao Chen; Yunmiao Guo
Journal:  J Exp Clin Cancer Res       Date:  2020-11-12

4.  CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.

Authors:  Qi-Hua Peng; Chun-Hua Wang; Hong-Min Chen; Rong-Xin Zhang; Zhi-Zhong Pan; Zhen-Hai Lu; Gao-Yuan Wang; Xin Yue; Wenlin Huang; Ran-Yi Liu
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

Review 5.  Fibroblast Subsets in Intestinal Homeostasis, Carcinogenesis, Tumor Progression, and Metastasis.

Authors:  Hao Dang; Tom J Harryvan; Lukas J A C Hawinkels
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

6.  Integrating Tumor Stroma Biomarkers With Clinical Indicators for Colon Cancer Survival Stratification.

Authors:  Yong Chen; Wenlong Wang; Bo Jiang; Lei Yao; Fada Xia; Xinying Li
Journal:  Front Med (Lausanne)       Date:  2020-12-07

7.  Colorectal cancer development is affected by the ECM molecule EMILIN-2 hinging on macrophage polarization via the TLR-4/MyD88 pathway.

Authors:  Paola Spessotto; Maurizio Mongiat; Eva Andreuzzi; Albina Fejza; Maurizio Polano; Evelina Poletto; Lucrezia Camicia; Greta Carobolante; Giulia Tarticchio; Federico Todaro; Emma Di Carlo; Melania Scarpa; Marco Scarpa; Alice Paulitti; Alessandra Capuano; Vincenzo Canzonieri; Stefania Maiero; Mara Fornasarig; Renato Cannizzaro; Roberto Doliana; Alfonso Colombatti
Journal:  J Exp Clin Cancer Res       Date:  2022-02-11

Review 8.  B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments.

Authors:  Yuan Wei; Chun-Xiang Huang; Xiao Xiao; Dong-Ping Chen; Hong Shan; Huanhuan He; Dong-Ming Kuang
Journal:  Oncogene       Date:  2021-06-29       Impact factor: 9.867

Review 9.  Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer.

Authors:  Gaetano Gallo; Giuseppina Vescio; Gilda De Paola; Giuseppe Sammarco
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

Review 10.  The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer.

Authors:  Beatriz Subtil; Alessandra Cambi; Daniele V F Tauriello; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.